BIOLASE Inc. [NASDAQ: BIOL] stock went on a downward path that fall over -4.78% on Tuesday, amounting to a one-week price decrease of less than -14.74%. The company report on November 23, 2021 that Nasdaq Grants BIOLASE 180-Day Extension To Meet Minimum Bid Price Requirement And Enters Into Favorable Credit Agreement Amendment.
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced its receipt of written notification from the Listing Qualification Department of The NASDAQ Stock Market (“Nasdaq”) granting BIOLASE’s request for a 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). BIOLASE now has until May 23, 2022 to regain compliance with the Bid Price Rule. Nasdaq’s extension notice has no immediate effect on the continued listing status of BIOLASE’s common stock, which remains listed on The NASDAQ Capital Market.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
If at any time until May 23, 2022, the bid price for BIOLASE’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive trading days, BIOLASE will regain compliance with the Bid Price Rule, and the matter will be closed. BIOLASE will continue to monitor the bid price for its common stock and consider various available options if BIOLASE’s common stock does not trade at a level that is likely to regain compliance with the Bid Price Rule. There can be no assurance that BIOLASE will regain compliance with the Bid Price Rule or maintain compliance with any of the other Nasdaq continued listing requirements during this extended compliance period.
Over the last 12 months, BIOL stock rose by 40.99%. The one-year BIOLASE Inc. stock forecast points to a potential upside of 81.33. The average equity rating for BIOL stock is currently 1.70, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $64.97 million, with 151.94 million shares outstanding and 149.03 million shares in the current float. Compared to the average trading volume of 2.17M shares, BIOL stock reached a trading volume of 5729435 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on BIOLASE Inc. [BIOL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BIOL shares is $2.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BIOL stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Benchmark Company have made an estimate for BIOLASE Inc. shares, keeping their opinion on the stock as Speculative Buy, with their previous recommendation back on June 19, 2019. While these analysts kept the previous recommendation, Singular Research raised their target price to Buy. The new note on the price target was released on April 25, 2017, representing the official price target for BIOLASE Inc. stock. Previously, the target price had yet another drop from $4 to $2.50, while WallachBeth kept a Hold rating on BIOL stock. On November 12, 2013, analysts decreased their price target for BIOL shares from 3.50 to 2.75.
The Average True Range (ATR) for BIOLASE Inc. is set at 0.03, with the Price to Sales ratio for BIOL stock in the period of the last 12 months amounting to 1.84. The Price to Book ratio for the last quarter was 2.10, with the Price to Cash per share for the same quarter was set at 0.22.
BIOL Stock Performance Analysis:
BIOLASE Inc. [BIOL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.74. With this latest performance, BIOL shares dropped by -28.22% in over the last four-week period, additionally sinking by -41.32% over the last 6 months – not to mention a rise of 40.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIOL stock in for the last two-week period is set at 21.50, with the RSI for the last a single of trading hit 14.80, and the three-weeks RSI is set at 27.00 for BIOLASE Inc. [BIOL]. The present Moving Average for the last 50 days of trading for this stock 0.5921, while it was recorded at 0.4467 for the last single week of trading, and 0.7245 for the last 200 days.
Insight into BIOLASE Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and BIOLASE Inc. [BIOL] shares currently have an operating margin of -81.37 and a Gross Margin at +27.10. BIOLASE Inc.’s Net Margin is presently recorded at -73.88.
Return on Total Capital for BIOL is now -79.85, given the latest momentum, and Return on Invested Capital for the company is -104.10. Return on Equity for this stock declined to -234.22, with Return on Assets sitting at -45.61. When it comes to the capital structure of this company, BIOLASE Inc. [BIOL] has a Total Debt to Total Equity ratio set at 182.14. Additionally, BIOL Total Debt to Total Capital is recorded at 64.56, with Total Debt to Total Assets ending up at 44.52. Long-Term Debt to Equity for the company is recorded at 181.23, with the Long-Term Debt to Total Capital now at 63.48.
Reflecting on the efficiency of the workforce at the company, BIOLASE Inc. [BIOL] managed to generate an average of -$124,659 per employee. Receivables Turnover for the company is 3.85 with a Total Asset Turnover recorded at a value of 0.62.BIOLASE Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 3.90.
BIOL Stock EPS
With the latest financial reports released by the company, BIOLASE Inc. posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.04/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -75.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BIOL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BIOLASE Inc. go to 20.00%.
BIOLASE Inc. [BIOL] Insider Position Details
There are presently around $9 million, or 19.40% of BIOL stock, in the hands of institutional investors. The top three institutional holders of BIOL stocks are: VANGUARD GROUP INC with ownership of 6,971,925, which is approximately 0% of the company’s market cap and around 0.40% of the total institutional ownership; PERKINS CAPITAL MANAGEMENT INC, holding 3,134,100 shares of the stock with an approximate value of $1.32 million in BIOL stocks shares; and BLACKROCK INC., currently with $1.27 million in BIOL stock with ownership of nearly 0.085% of the company’s market capitalization.
Positions in BIOLASE Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 24 institutional holders increased their position in BIOLASE Inc. [NASDAQ:BIOL] by around 5,239,630 shares. Additionally, 14 investors decreased positions by around 378,764 shares, while 15 investors held positions by with 16,931,010 shares. The mentioned changes placed institutional holdings at 22,549,404 shares, according to the latest SEC report filing. BIOL stock had 12 new institutional investments in for a total of 3,044,194 shares, while 6 institutional investors sold positions of 61,703 shares during the same period.